Last reviewed · How we verify

NCT01388569

Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim

Completed Last updated 17 May 2017
What this trial tests

trial testing flow cytometry in Melanoma (Skin) in 48 participants. Completed in 28 September 2011.

Timeline
28 June 2011
Primary endpoint
28 September 2011
28 September 2011

Quick facts

Lead sponsorEastern Cooperative Oncology Group
StatusCompleted
Study typeOBSERVATIONAL
Enrollment48
Start date28 June 2011
Primary completion28 September 2011
Estimated completion28 September 2011

Drugs / interventions tested

Conditions studied

Sponsor

Eastern Cooperative Oncology Group

Who can join

Adults 18 to 120, any sex, with Melanoma (Skin). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Studying samples of blood from patients treated with sargramostim in the laboratory may help doctors learn more about the effects of sargramostim on cells. It may also help doctors understand how patients respond to treatment. PURPOSE: This research trial studies biomarkers in blood samples from patients with stage IV melanoma previously treated with sargramostim.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of flow cytometry

Trials testing the same drug.

Other recruiting trials for Melanoma (Skin)

Currently open trials in the same condition.

Other Eastern Cooperative Oncology Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01388569.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing